SCHEMBL1341018

SCHEMBL1341018

CC(C)CON(C(=O)CC(=O)Nc1nc(CC(=O)O)c(Sc2ccccn2)s1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 5/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.33
OPRK1 P41145 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343073 0.95 GCK (0.39) GCKSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL1342682 0.94 GCK (0.45) GCKSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL1342577 0.87 TSHR (0.36) SMN1; SMN2ALDH1A1MAPTKMT2AMEN1
SCHEMBL1342841 0.86 MAPT (0.32) GCKSMN1; SMN2MAPTKMT2AMEN1
SCHEMBL1340467 0.85 GCK (0.43) GCKMAPTKMT2AMEN1NPC1
SCHEMBL1341013 0.82 GCK (0.41) GCKSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL1343172 0.81 GLS (0.36) SMN1; SMN2ALDH1A1MAPTKMT2AMEN1
SCHEMBL1342198 0.81 GCK (0.44) GCKSMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL1343019 0.81 GCK (0.44) GCKALDH1A1MAPTKMT2AMEN1
SCHEMBL1343070 0.81 MAPT (0.40) GCKSMN1; SMN2ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 GCK 1/4885SMN1; SMN2 2958/4885ALDH1A1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.